Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Finding, Efficacy and Safety Study of YY-351 in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Previous diagnosis of Type 2 diabetes(more than 3months)~* Patients aged over 18 years~* FPG levels in the range : 126 - 270mg/dL or HbA1c : 7.0 - 12.0%~Exclusion Criteria:~* Pregnant women, Breast feeding, or actively trying to be come pregnant~* Patients with Type 1 DM, gestational diabetes or secondary diabetes~* FPG levels in the range : ≥ 270mg/dL HbA1c : \< 7.0, \>12.0%~* Patient who take the medicine which may affect to blood sugar control (i.e.systemic glucocorticoid)~* Patients with diabetic complications or the history of a case that would affect to efficacy and safety evaluation (i.e. Thyroid disorder, Cushing's Syndrome, Multiple ovarian cystoma, pheochromocytoma)~* Patients with Chronic hepatitis, hepatitis B, C (except healthy HBV carrier) or Liver diseases (AST or/and ALT \>2 × ULN(upper limit normal))~* Patients with Kidney disorder (Cr\>2.0)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): YY-351, PO, 1T tid. / Placebo, 1T tid.
- 2 (Type: EXPERIMENTAL): YY-351. PO, 2T bid. / Placebo 2T qd.
- 3 (Type: EXPERIMENTAL): YY-351, PO, 2T tid.
- 4 (Type: PLACEBO_COMPARATOR): Placebo, PO, 2T tid.

Based on this trial design, predict the completion outcome and termination type (if applicable).